Bacil Pharma Limited (BOM:524516)

Bacil Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Selling, General & Admin	1.11	1.38	0.99	0.86	0.6	0.52
Other Operating Expenses	1.7	1.14	0.88	0.91	0.95	1.09
Operating Expenses	2.81	2.53	1.89	1.8	1.59	1.67
Operating Income	-2.81	-2.53	-1.89	-1.8	-1.59	-1.67
Interest Expense	-0.01	-0.01	-0.01	-0.01	-0.01	-0.05
Interest & Investment Income	0.83	0.83	0.3	0.29	0.58	0.74
Other Non Operating Income (Expenses)	5.26	0.4	-	-	-	-
EBT Excluding Unusual Items	3.28	-1.31	-1.6	-1.52	-1.02	-0.97
Gain (Loss) on Sale of Investments	5.38	5.38	1.01	0.5	-0.63	-1.42
Gain (Loss) on Sale of Assets	-	-	-	-	-36.95	-
Pretax Income	8.66	4.08	-0.59	-1.02	-38.6	-2.4
Income Tax Expense	2.3	0.03	0	-0	-0	-0
Net Income	6.37	4.04	-0.59	-1.02	-38.6	-2.39
Net Income to Common	6.37	4.04	-0.59	-1.02	-38.6	-2.39
Shares Outstanding (Basic)	10	6	6	6	6	6
Shares Outstanding (Diluted)	10	6	6	6	6	6
Shares Change (YoY)	71.68%	6.92%	-1.47%	1.71%	0.99%	-0.04%
EPS (Basic)	0.62	0.64	-0.10	-0.17	-6.55	-0.41
EPS (Diluted)	0.62	0.64	-0.10	-0.17	-6.55	-0.41
Free Cash Flow	-	4.01	-0.03	-1.48	-40.09	-3.98
Free Cash Flow Per Share	-	0.64	-0.01	-0.25	-6.80	-0.68
EBITDA	-2.81	-2.53	-1.87	-1.77	-1.55	-1.62
D&A For EBITDA	0	0.01	0.02	0.03	0.04	0.05
EBIT	-2.81	-2.53	-1.89	-1.8	-1.59	-1.67
Effective Tax Rate	26.50%	0.85%	-	-	-	-
Revenue as Reported	11.58	6.61	1.31	1.15	0.58	0.74

Source: S&P Global Market Intelligence. Standard template. Financial Sources.